Clinical trials: Heart Failure with Reduced Ejection Fraction HFrEF
Heart Failure With Reduced Ejection Fraction
Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure
A randomized controlled trial to compare the efficacy of an electronic health record-based alert informing providers about evidence-based medications for HFrEF versus usual care (no alert) in outpatient clinics across a single…
- Trial name
- PROMPT-HF (NCT04514458)
- Testing
- Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)
- Where
- United States
- Volunteers
- 1,410 people
- Sponsor
- Yale University
Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had…
- Trial name
- VICTOR (NCT05093933)
- Testing
- Vericiguat
- Where
- 519 sites in United States, Argentina and 34 more
- Volunteers
- 6,106 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Heart Failure With Reduced Ejection Fraction
Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure
Dapagliflozin is a molecule belonging to the class of sodium-glucose transporter type 2 (SGLT2-i) inhibitors. This type of drug, initially used in the treatment of diabetes mellitus, has in recent years demonstrated significant…
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Left Ventricle Remodeling, Sleep Apnea
- Trial name
- NCT05770167
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Centro Cardiologico Monzino
Heart Failure
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
Angiotensin-neprilysin inhibitors (ARNI) are beneficial in patients with heart failure with reduced ejection fraction. No study evaluating ARNI has been conducted in sub-Saharan Africa (except South Africa) yet, where heart…
- Trial name
- NCT06704633
- Testing
- Sacubitril / Valsartan Oral Tablet
- Where
- Tanzania
- Volunteers
- 298 people
- Sponsor
- Martin Rohacek
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Beta 3 Agonist Treatment in Heart Failure
Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with chronic heart failure.
- Trial name
- Beat-HF (NCT01876433)
- Testing
- Mirabegron
- Where
- 3 sites in Australia, Denmark
- Volunteers
- 70 people
- Sponsor
- Henning Bundgaard
Heart Failure - NYHA II - IV, Cardiac Fibrosis
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal outcomes in patients with…
- Conditions
- Heart Failure - NYHA II - IV, Cardiac Fibrosis, Cardiac Remodeling
- Trial name
- NCT06901609
- Testing
- SGLT2 inhibitor (Dapagliflozin 10mg)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Ain Shams University
Heart Failure
Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction
Study hypothesis: Comparing the effect of digoxin and ivabradine in chronic heart failure patients with a left ventricular ejection of 35% or lower and sinus rhythm with heart rate 70 beats per minute or higher, and who are…
- Trial name
- DIVA-REF (NCT02046044)
- Testing
- Digoxin, Ivabradine
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Kocaeli University
Heart Failure With Reduced Ejection Fraction
Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure
RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.
- Trial name
- RECOVER-HF (NCT06552637)
- Testing
- Synchronized Diaphragmatic Stimulation
- Where
- 5 sites in United States, Georgia
- Volunteers
- 270 people
- Sponsor
- VisCardia Inc.
Heart Failure With Reduced Ejection Fraction NYHA Class III-IV
Beta 3 Agonist Treatment in Heart Failure-2
Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with moderate to severe chronic heart failure (LVEF<35%, NYHA…
- Trial name
- BEAT-HF II (NCT03926754)
- Testing
- Mirabegron
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Henning Bundgaard
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
The goal of this clinical trial is to learn which iron treatment works better for adults with congestive heart failure and low iron levels: intravenous (IV) iron given through a vein or oral (PO) iron taken by mouth.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency
- Trial name
- IRONICA (NCT07053475)
- Testing
- Ferric Carboxymaltose, Ferrous Sulfate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Syed Hamza Mufarrih
Heart Failure With Reduced Ejection Fraction
A Single-centre Research Study to Evaluate the Care4Today® Heart Failure Platform.
A research study to evaluate the impact of a novel care pathway for patients diagnosed with Heart Failure within Chiltern CCG, supported by an integrated clinical patient record.
- Trial name
- NCT04371731
- Testing
- Care4todayheart failure platform
- Volunteers
- 182 people
- Sponsor
- Buckinghamshire Healthcare NHS Trust
Heart Failure With Reduced Ejection Fraction
Effect of the MobiusHD® in Patients With Heart Failure
This is a prospective, multi-center, open-label clinical trial intended to evaluate the safety and effectiveness of the MobiusHD® in patients with heart failure and reduced ejection fraction.
- Trial name
- HF-FIM (NCT04590001)
- Testing
- MobiusHD
- Where
- 17 sites in Australia, Canada and 3 more
- Volunteers
- 50 people
- Sponsor
- Vascular Dynamics, Inc.
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
This study will evaluate the V-Wave Ventura Interatrial shunt. The Shunt is a small, hourglass-shaped device implanted in the dividing wall (septum) between the right and left atria (top chambers) of the heart placed during a…
- Conditions
- Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic, Heart Failure New York Heart Association Class III, Heart Failure Congestive
- Trial name
- RELIEVE-HFrEF (NCT07696975)
- Testing
- Implantation of the V-Wave Interatrial shunt
- Volunteers
- 250 people
- Sponsor
- V-Wave Ltd
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Heart Failure With Reduced Ejection Fraction, Dyssynchrony
Pacertool Early Feasibility Study - Safety and Performance
The study is a non-randomized, two-part, open label, prospective single-site, single arm, safety and performance study. The study is designed to collect acute and long-term clinical data and user reported outcome data from using…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Dyssynchrony, Medical Device Performance
- Trial name
- NCT06103539
- Testing
- Cardiac catheterization and evoked response to cardiac stimulation
- Where
- Georgia
- Volunteers
- 50 people
- Sponsor
- Pacertool AS
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
This study will address whether the additional use of Ferric Derisomaltose on top of standard care will improve exercise capacity and quality of life in patients with acute heart failure and iron deficiency.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Iron Deficiency, Acute Heart Failure
- Trial name
- COREVIVE-HFrEF (NCT05971732)
- Testing
- Ferric derisomaltose
- Where
- China
- Volunteers
- 146 people
- Sponsor
- China-Japan Friendship Hospital
Acute Heart Failure, Chronic Kidney Diseases
Natriuresis-Guided Diuretic Therapy in Patients With Acute Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
To investigate the effectiveness and feasibility of natriuresis-guided diuretic therapy as a personalized approach to managing acute heart failure in patients with underlying chronic kidney disease and its effect on short term…
- Trial name
- NCT06203236
- Testing
- Furosemide 20 MG, diuretic therapy
- Volunteers
- 300 people
- Sponsor
- Assiut University
Heart Failure With Reduced Ejection Fraction
Efficacy and Safety of Lactoferrin in Heart Failure Patients
This study will be conducted to determine the efficacy and safety of lactoferrin versus oral iron versus lactoferrin plus oral iron as an add on therapy in reduced ejection fraction heart failure patients with iron deficiency.
- Trial name
- NCT06427200
- Testing
- oral Iron, Lactoferrin, lactoferrin and oral iron
- Volunteers
- 114 people
- Sponsor
- Cairo University
HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease
Swedish Cardiac And Renal Failure Study-1
Previous studies have shown that patients with heart failure with reduced pumping function and preserved kidney function experience improved symptoms, longer survival, and fewer hospitalizations when treated with medications such…
- Trial name
- SCARF-1 (NCT07029503)
- Testing
- Eplerenone
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet